Cancel
Matthew Plunkett
Chief Financial Officer
@
Apollomics
v9jgjfg.z40vd5b2@77qg37f3brv73.jb0
Sign up to see email
Known information
- Holds a Ph.D. in organic chemistry from the University of California, Berkeley
- Received a B.S. in chemistry from Harvey Mudd College
- Brings over 25 years of diverse strategic and financial experience within the biopharmaceutical sector
- Most recently served as Chief Financial Officer at Aeovian Pharmaceuticals
- Previously was Chief Financial Officer at Imago Biosciences, where he led the company's $155 million Nasdaq initial public offering
- Was Chief Financial Officer at Nkarta Therapeutics, leading the efforts for its $290 million Nasdaq IPO
- Held the position of Chief Business Officer at CTI BioPharma, where he led various financing and corporate development transactions
- Earlier in his career, held various positions at CIBC World Markets and its U.S. successor Oppenheimer & Co., including Managing Director, Head of West Coast Biotechnology
About Apollomics
Apollomics is a biopharmaceutical company focused on developing innovative oncology therapies, including targeted treatments and immune system enhancers, with operations in the U.S., China, and Australia.
Report inaccurate information
